Glioblastoma Multiforme Treatment Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Glioblastoma Multiforme Treatment Market 

5.1. COVID-19 Landscape: Glioblastoma Multiforme Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Glioblastoma Multiforme Treatment Market, By Treatment

8.1. Glioblastoma Multiforme Treatment Market, by Treatment, 2024-2033

8.1.1 Surgery

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Radiation Therapy

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Chemotherapy

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Targeted Therapy

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Tumor Treating Field (TTF) Therapy

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Immunotherapy

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Glioblastoma Multiforme Treatment Market, By Drug Class

9.1. Glioblastoma Multiforme Treatment Market, by Drug Class, 2024-2033

9.1.1. TMZ

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Carboplatin

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Cisplatin

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Bevacizumab

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Glioblastoma Multiforme Treatment Market, By End-user 

10.1. Glioblastoma Multiforme Treatment Market, by End-user, 2024-2033

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Clinics

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Ambulatory Surgical Centers

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Glioblastoma Multiforme Treatment Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.1.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.3. Market Revenue and Forecast, by End-user (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End-user (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End-user (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.2.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.3. Market Revenue and Forecast, by End-user (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End-user (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End-user (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End-user (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End-user (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.3. Market Revenue and Forecast, by End-user (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End-user (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End-user (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End-user (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End-user (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.3. Market Revenue and Forecast, by End-user (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End-user (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End-user (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End-user (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End-user (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.3. Market Revenue and Forecast, by End-user (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End-user (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Treatment (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End-user (2021-2033)

Chapter 12. Company Profiles

12.1. Merck & Co., Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Amgen, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. F. Hoffmann-La Roche Ltd.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Pfizer Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Teva Pharmaceutical Industries Ltd.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Sun Pharmaceutical Industries Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Arbor Pharmaceuticals, LLC

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Amneal Pharmaceuticals

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Karyopharm Therapeutics, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms